KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Exchange Rate Effect (2017 - 2025)

Historic Exchange Rate Effect for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$694000.0.

  • Amneal Pharmaceuticals' Exchange Rate Effect fell 1001428.57% to -$694000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year decrease of 371206.9%. This contributed to the annual value of -$999000.0 for FY2024, which is 163692.31% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Exchange Rate Effect stood at -$694000.0, which was down 1001428.57% from -$307000.0 recorded in Q2 2025.
  • Amneal Pharmaceuticals' Exchange Rate Effect's 5-year high stood at $767000.0 during Q1 2023, with a 5-year trough of -$3.7 million in Q4 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' median Exchange Rate Effect value was -$301000.0 (recorded in 2023), while the average stood at -$420315.8.
  • In the last 5 years, Amneal Pharmaceuticals' Exchange Rate Effect soared by 14879.13% in 2023 and then plummeted by 1001428.57% in 2025.
  • Amneal Pharmaceuticals' Exchange Rate Effect (Quarter) stood at $178000.0 in 2021, then tumbled by 2200.56% to -$3.7 million in 2022, then soared by 105.38% to $201000.0 in 2023, then plummeted by 468.16% to -$740000.0 in 2024, then grew by 6.22% to -$694000.0 in 2025.
  • Its last three reported values are -$694000.0 in Q3 2025, -$307000.0 for Q2 2025, and -$470000.0 during Q1 2025.